-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Antibacterial therapy is one of the commonly used therapies in clinical practice
.
Data show that from 2016 to 2019, the scale of China's antimicrobial drug market showed a slow growth trend
.
It is predicted that from 2022 to 2030, the scale of China's antimicrobial drug market may show a trend of first rising and then falling
.
According to statistics, in 2020, the size of China's antimicrobial drug market will be 124.
4 billion yuan, a significant decline
.
In 2021, the scale of China's antimicrobial drug market will rebound slightly
.
It is predicted that the compound annual growth rate of the market size of antimicrobial drugs in China from 2022 to 2025 is about 2.
1%, and the compound annual growth rate from 2025 to 2030 is -1.
9%, showing a trend of first rising and then falling
.
Among them, the market scale of multidrug-resistant Gram-negative bacteria antibiotics in China is on the rise as a whole
.
It is understood that antibacterial drugs are widely used, and enterprises are constantly making new breakthroughs in the development of antibacterial drugs
.
For example, SCYNEXIS recently announced that its innovative oral antifungal investigational therapy ibrexafungerp has received positive interim results in two Phase 3 clinical trials, continuing to demonstrate ibrexafungerp's potential to treat difficult-to-treat fungal infections in the hospital setting
.
The data show that Ibrexafungerp is a glucan synthase inhibitor with a unique structure, which combines the good activity of glucan synthase inhibitors with the potential flexibility of oral and intravenous administration, which is expected to be used in hospitalization and Widely used in outpatient settings
.
Currently, the drug is being developed to treat fungal infections mainly caused by Candida and Aspergillus
.
It exhibits broad-spectrum antifungal activity in in vitro and in vivo studies
.
For the use of antibacterial drugs, the correct and rational use of antibacterial drugs has attracted more and more attention
.
According to the industry, the rational application of drugs is the key to improving efficacy and reducing adverse drug reactions.
In drug compatibility, it is necessary to exert the effect of drugs and reduce the mutual interference and influence of drugs due to compatibility
.
For example, cephalosporins have been widely used in clinical practice in recent years, and their adverse reactions and incompatibilities have been paid more and more attention
.
Because cephalosporins have certain toxic and side effects on the liver and kidney, when they are combined with drugs that may lead to impaired liver and kidney function, sufficient attention should be paid to cephalosporins and strong diuretics (furosemide, edenic acid, etc.
).
, Bumetanide, etc.
), antineoplastic drugs (carbazide, streptozocin, etc.
) and aminoglycoside antibiotics are equivalent, can increase nephrotoxicity; with probenecid can inhibit the excretion of cephalosporins in the kidneys , the blood concentration increased by 30%
.
It is understood that in order to ensure medical quality and medical safety, the Sichuan Provincial Health and Health Commission recently released the "Sichuan Province Antimicrobial Clinical Application Hierarchical Management Catalog (2022 Edition)" (referred to as the "Catalog")
.
After sorting out the drug appointments, it was found that the new version of the "Catalogue" once again tightened the application level of a variety of antibacterial drugs
.
In the unrestricted category, 13 drugs are no longer available, including oxytetracycline, benzathine penicillin*, penicillin G*, amoxicillin/clavulanate (oral), cefradine, cefixime, trimethoprim *, sulfamethoxazole*, compound sulfamethoxazole* (oral), clindamycin, lincomycin, nitrofurantoin*, 5-flucytosine*
.
But at the same time, the clinical use of 8 drugs has also been increased, including flucloxacillin, cefotaxime, clarithromycin, josamycin, norfloxacin, ciprofloxacin (oral), rifampicin (oral), itraconazole (oral capsule)
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Data show that from 2016 to 2019, the scale of China's antimicrobial drug market showed a slow growth trend
.
It is predicted that from 2022 to 2030, the scale of China's antimicrobial drug market may show a trend of first rising and then falling
.
According to statistics, in 2020, the size of China's antimicrobial drug market will be 124.
4 billion yuan, a significant decline
.
In 2021, the scale of China's antimicrobial drug market will rebound slightly
.
It is predicted that the compound annual growth rate of the market size of antimicrobial drugs in China from 2022 to 2025 is about 2.
1%, and the compound annual growth rate from 2025 to 2030 is -1.
9%, showing a trend of first rising and then falling
.
Among them, the market scale of multidrug-resistant Gram-negative bacteria antibiotics in China is on the rise as a whole
.
It is understood that antibacterial drugs are widely used, and enterprises are constantly making new breakthroughs in the development of antibacterial drugs
.
For example, SCYNEXIS recently announced that its innovative oral antifungal investigational therapy ibrexafungerp has received positive interim results in two Phase 3 clinical trials, continuing to demonstrate ibrexafungerp's potential to treat difficult-to-treat fungal infections in the hospital setting
.
The data show that Ibrexafungerp is a glucan synthase inhibitor with a unique structure, which combines the good activity of glucan synthase inhibitors with the potential flexibility of oral and intravenous administration, which is expected to be used in hospitalization and Widely used in outpatient settings
.
Currently, the drug is being developed to treat fungal infections mainly caused by Candida and Aspergillus
.
It exhibits broad-spectrum antifungal activity in in vitro and in vivo studies
.
For the use of antibacterial drugs, the correct and rational use of antibacterial drugs has attracted more and more attention
.
According to the industry, the rational application of drugs is the key to improving efficacy and reducing adverse drug reactions.
In drug compatibility, it is necessary to exert the effect of drugs and reduce the mutual interference and influence of drugs due to compatibility
.
For example, cephalosporins have been widely used in clinical practice in recent years, and their adverse reactions and incompatibilities have been paid more and more attention
.
Because cephalosporins have certain toxic and side effects on the liver and kidney, when they are combined with drugs that may lead to impaired liver and kidney function, sufficient attention should be paid to cephalosporins and strong diuretics (furosemide, edenic acid, etc.
).
, Bumetanide, etc.
), antineoplastic drugs (carbazide, streptozocin, etc.
) and aminoglycoside antibiotics are equivalent, can increase nephrotoxicity; with probenecid can inhibit the excretion of cephalosporins in the kidneys , the blood concentration increased by 30%
.
It is understood that in order to ensure medical quality and medical safety, the Sichuan Provincial Health and Health Commission recently released the "Sichuan Province Antimicrobial Clinical Application Hierarchical Management Catalog (2022 Edition)" (referred to as the "Catalog")
.
After sorting out the drug appointments, it was found that the new version of the "Catalogue" once again tightened the application level of a variety of antibacterial drugs
.
In the unrestricted category, 13 drugs are no longer available, including oxytetracycline, benzathine penicillin*, penicillin G*, amoxicillin/clavulanate (oral), cefradine, cefixime, trimethoprim *, sulfamethoxazole*, compound sulfamethoxazole* (oral), clindamycin, lincomycin, nitrofurantoin*, 5-flucytosine*
.
But at the same time, the clinical use of 8 drugs has also been increased, including flucloxacillin, cefotaxime, clarithromycin, josamycin, norfloxacin, ciprofloxacin (oral), rifampicin (oral), itraconazole (oral capsule)
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
